Catalog No.S7609 Synonyms: GW69A, GW554869A

For research use only.

GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.

GW4869 Chemical Structure

CAS No. 6823-69-4

Selleck's GW4869 has been cited by 30 publications

Purity & Quality Control

Choose Selective Phospholipase (e.g. PLA) Inhibitors

Other Phospholipase (e.g. PLA) Products

Biological Activity

Description GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.
SMase [1]
(Cell-free assay)
1 μM
In vitro

GW4869 inhibits N-SMase not only in vitro but also in a cellular model. GW4869 does not significantly impair TNF-induced NF-κB translocation to nuclei. Therefore, GW4869 does not interfere with other key TNF-mediated signaling effects. GW4869 is able, in a dose-dependent manner, to significantly protect from cell death as measured by nuclear condensation, caspase activation, PARP degradation, and trypan blue uptake. These protective effects are accompanied by significant inhibition of cytochrome c release from mitochondria and caspase 9 activation, therefore localizing N-SMase activation upstream of mitochondrial dysfunction. At up to 150 μM, GW4869 does not inhibit the cloned human A-SMase. GW4869 shows no or minor inhibitory activity versus other hydrolytic enzymes, such as bacterial phosphatidylcholine-PLC and bovine protein phosphatase 2A, and it shows significantly higher activity versus the rat brain enzyme compared with the human lyso-PAF PLC[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M1nQW2Z2dmO2aX;uJIF{e2G7 NInLfWEyOC1{MDFOwG0> M1vWUpRp\SCjZHTpeIlwdiCxZjCxNEDPxE1iR2e0PFY6KHOrZ37p[olk[W62bImgbY5pcWKrdHXkJHRPTi2rbnT1Z4VlKFOPIHj5[JJwdHm|aYOsJJdp\XKnYYOgNlAh|ryPIH;mJJRp\SClb33wc5Vv\CCycn;0[YN1\WRiY3;tdIxmfGWueTDmdo9uKHSqZTDsc5N{KG:oIIPwbIlv\2:veXXsbY4> Mk\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzNUSwPVgoRjF{MUW0NFk5RC:jPh?=
OPM2 MlzvVJJwdGmoZYLheIlwdiCjc4PhfS=> NVHHTHVCOCxiMT6yOUwhOi53LDC1MEAyOCxiMkCsJFQxKM7:bX;sM2w> M2PD[lI1KGh? Mn;xeIhmKGOnbHygdJJwdGmoZYLheIlwdiC{YYTlJJdieyCrbnPy[YF{\WRiYX\0[ZIhT1d2OE[5JJRz\WG2bXXueE4hXGinIHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKHejczDvcox6KHOrZ37p[olk[W62IIfo[Y4hfGinIHPvcoNmdnS{YYTpc44hd2ZiR2e0PFY6KHejczC0NEDPxG2xbD;MJI9zKGirZ3jldk4> M3vJS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEW4Nlk1Lz5{OEi1PFI6PDxxYU6=
RPMI-8226 NFjQW4tE\WyuII\pZYJqdGm2eTDhd5NigQ>? MV[3NkBp M4\JfoN6fG:2b4jpZ{B1dyCjIIDhcoVtKG:oIF3NJINmdGxibHnu[ZM> M1vN[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkGxOVc{Lz5{OEKxNVU4OzxxYU6=
NCI-H929 MV\D[YxtKH[rYXLpcIl1gSCjc4PhfS=> MXG3NkBp NWXucIFZ[3m2b4TvfIlkKHSxIHGgdIFv\Wxib3[gUW0h[2WubDDsbY5mew>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzMUW3N{c,Ojh{MUG1O|M9N2F-
JJN3 NWXUbIRWS2WubDD2bYFjcWyrdImgZZN{[Xl? MlfhO|IhcA>? MX7jfZRwfG:6aXOgeI8h[SCyYX7lcEBw\iCPTTDj[YxtKGyrbnXz MmHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MUG1O|MoRjJ6MkGxOVc{RC:jPh?=
U266 NUTST|NCS2WubDD2bYFjcWyrdImgZZN{[Xl? MkPYO|IhcA>? MlnMZ5l1d3SxeHnjJJRwKGFicHHu[Ywhd2ZiTV2gZ4VtdCCuaX7ldy=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzMUW3N{c,Ojh{MUG1O|M9N2F-
Daudi NHf0OmxE\WyuII\pZYJqdGm2eTDhd5NigQ>? MmLpO|IhcA>? MkX3co91KGO7dH;0c5hq[yC2bzDuc44uVU1iY3XscEBtcW6nczDvdkBRSk2Fcx?= M2TJZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkGxOVc{Lz5{OEKxNVU4OzxxYU6=
Jurkat NHvRNXRE\WyuII\pZYJqdGm2eTDhd5NigQ>? M1LLeFczKGh? MnPNco91KGO7dH;0c5hq[yC2bzDuc44uVU1iY3XscEBtcW6nczDvdkBRSk2Fcx?= M2PPWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkGxOVc{Lz5{OEKxNVU4OzxxYU6=
K562 NGHGOJdE\WyuII\pZYJqdGm2eTDhd5NigQ>? NVvj[VJ[PzJiaB?= MmTlco91KGO7dH;0c5hq[yC2bzDuc44uVU1iY3XscEBtcW6nczDvdkBRSk2Fcx?= NFLDZXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKxNVU4Oyd-MkiyNVE2PzN:L3G+
PBMCs MVXD[YxtKH[rYXLpcIl1gSCjc4PhfS=> NUjXN5l[PzJiaB?= NX3UN|VQdm:2IHP5eI91d3irYzD0c{Bvd25vTV2gZ4VtdCCuaX7ld{BweiCSQl3Ddy=> M{PiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkGxOVc{Lz5{OEKxNVU4OzxxYU6=
Methods Test Index PMID
Immunofluorescence Nrf2 29794115
In vivo Systemic administration of GW4869 does not alter the ceramide or sphingomylein content of liver, heart or skeletal muscle but does decrease the ceramide content and increase the sphingomyelin content in brain. Inhibition of nSMase2 with GW4869 slowed learning. Mice administered GW4869 do not progressively decrease latency to locate the hidden platform with repeated training trials, suggesting that they has difficulty learning to use spatial cues to navigate the pool[2]. Intraperitoneal injection of GW4869 reduces the levels of brain and serum exosomes, brain ceramide, and Aβ1-42 plaque load. GW4869 reduces amyloid plaque formation in vivo by preventing exosome secretion. GW4869 may have a low toxicity at levels needed to achieve a biological effect from nSMase2 inhibition[3].

Protocol (from reference)

Cell Research:


  • Cell lines: MCF7 cells
  • Concentrations: 10-20 μM
  • Incubation Time: 30 min
  • Method:

    MCF7 human breast cancer cells are routinely cultured in RPMI 1640 containing 10% FBS at 37 °C in 5% CO2. Unless otherwise indicated, for treatment, cells are seeded at 1.7 × 106 cells/10-cm culture dish in 10 ml of complete medium; after 24 h, the medium is replaced with 7 ml of RPMI 1640 containing 2% FBS and 25 mM Hepes, pH 7.5, and the cells are rested for 2 h prior to treatment. GW4869 is routinely stored at −80 °C as a 1.5 mM stock suspension in Me2SO. Right before use, the suspension is solubilized by the addition of 5% methane sulfonic acid (MSA) (2.5 μl of 5% MSA in sterile double-distilled H2O are added to 50 μl of GW4869 stock suspension; therefore, the concentration of the GW4869 stock solution at the time of the experiments is 1.43 mM). The suspension is mixed and warmed up at 37 °C until clear. Cells are preincubated with the inhibitor for 30 min prior to treatment with TNF. Control cells are treated with Me2SO containing 5% MSA, similarly to the samples receiving the GW4869 solution. When different doses of GW4869 are tested, amounts of vehicle solution are added in order to equal the volume of GW4869 used for the highest dose.

Animal Research:


  • Animal Models: Mice with a complete loss of nSMase2 activity (background: C57BL/6J mice)
  • Dosages: 1.25 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 577.5


CAS No. 6823-69-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C=CC3=CC=C(C=C3)C=CC(=O)NC4=CC=C(C=C4)C5=NCCN5.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy GW4869 | GW4869 supplier | purchase GW4869 | GW4869 cost | GW4869 manufacturer | order GW4869 | GW4869 distributor